Search This Blog

Sunday, 25 June 2017

EACPT 2017 Congress underway in Prague

The EACPT 2017 Congress is underway in Prague from 24th-27th June with 566 participants from all 5 continents - 28% from beyond the European Region, from Australia to China, Japan and South Korea to the USA.

Professor Pertti J. Neuvonen
The Congress includes 22 sessions with Keynote Lectures on current issues for research, education and clinical practice on safe and effective use of medicines. 

Almost 500 oral and poster presentations will be presented by delegates from the European Region and around the world  

During the opening session on Saturday 24th June, the 2017 EACPT Lifetime Achievement Award was presented to Professor Pertti J. Neuvonen, Finland. 
Paoletti Medal Awards
The Rodolfo Paoletti Medal for Distinction in European Pharmacology at the 2017 EACPT Congress in Prague was presented on 25th June to current EACPT President Professor Tabassome Simon from Paris and EACPT Past-President Professor Gonzalo Calvo from Barcelona. The awards were announced by EPHAR Past-President Professor Thomas Griesbacher and EPHAR President-Elect Mojka Kržan.
 
Further scientific Awards will be presented later during the Congress.
During the Congress, delegates will have the opportunity to network with global experts and trainees in the fields of research, clinical practice, the biotechnology sector, regulation and health policy. There will also be updates on the activities of the EACPT Working Groups for Research, Education, Regulation and Young Pharmacologists.

More on the Prague Congress

Future EACPT Congresses:
- 2019 Stockholm
- 2021 Athens
- 2023 Rotterdam
 
The EACPT was founded 25 years ago and now includes as members all national organisations for clinical pharmacology in Europe, as well as organisations from further afield internationally. The EACPT aims to provide educational and scientific support for the more than 4000 individual professionals interested in clinical pharmacology and therapeutics throughout the European region, with its congresses attended by a global audience. The EACPT also advises policy makers on how the specialty can contribute to human health and wealth.
Clinical Therapeutics, the Official Journal of EACPT.

Rodolfo Paoletti Medal for Distinction in European Pharmacology awarded to EACPT Current and Past Presidents.


The Rodolfo Paoletti Medal for Distinction in European Pharmacology at the 2017 EACPT Congress in Prague has been presented to current EACPT President Professor Tabassome
Simon from Paris and EACPT Past-President Professor Gonzalo Calvo from Barcelona. The awards were presented by EPHAR Past-President Professor Thomas Griesbacher and EPHAR President-Elect Mojka Kan.
Prof. Mojca KRŽAN, EPHAR, Prof. Tabassome Simon - EACPT and Prof. Thomas Griesbacher - EPHAR
Prof. Gonzalo Calvo - EACPT with Mojka Kržan. - EPHAR.


The Rodolfo Paoletti Medal for Distinction in European Pharmacology is named after Rodolfo Paoletti, first President of the Federation of European Pharmacological Societies (1990-1997). The medal was created by EPHAR in 2014 to honour distinguished pharmacologists who have achieved merits for the discipline of Pharmacology in Europe.

Tabassome Simon has since 2015 been the Chair of the European Association for Clinical Pharmacology and Therapeutics (EACPT). She is Professor of Clinical Pharmacology in the Department of Pharmacology, AP-HP, Saint-Antoine Hospital, Pierre and Marie Curie University (UPMC) in Paris, France. She is also Member of the Board of the National Union of University Hospital Pharmacologists, of the Research Committee of the French Society of Cardiology, the strategic committee of the Pierre et Marie Curie University (UPMC-Paris 06), and the Research committee for the cancer university Institute (IUC-Paris 06). Pr Simon is the Director of the Clinical Research platform of the East of Paris, including the Clinical Research Unit (URC-EST: http://www.urcest.chusa.upmc.fr/), the clinical Research Center, and the BioBank Research Center of UPMC-Paris 06 University. Currently, the clinical research platform coordinates several multicenter national and international studies throughout centers in France. Read more ... 

Gonzalo Calvo was President of the European Association of Clinical Pharmacology and Therapeutics (EACPT) from 2011 - 2015.Gonzalo Calvo is a consultant in Clinical Pharmacology at the Hospital Clinic of Barcelona and Associate Professor of Pharmacology at the University of Barcelona (UB). After receiving his medical degree, he specialized in Clinical Pharmacology at CSU Vall d’Hebron (1993) and became a doctor of medicine in 1997. Prof. Calvo’s main area of expertise is drug regulation, with particular interest in cardiovascular and onco-haematology. He has been principal investigator of around 50 clinical trials and has co-authored 85 peer-reviewed papers and 2 books. From 2002 to 2011, he represented the Spanish Agency on Medicines and Healthcare Products (AEMPS) at the EMA Committee for Human Medicinal Products (CHMP) as rapporteur of more than 60 new drug applications. Prof. Calvo has since 2013 been the co-chair of the European Medicines Agency Healthcare Professional Working Party. 

The Rodolfo Paoletti Medal for Distinction in European Pharmacology is named after Rodolfo Paoletti, first President of the Federation of European Pharmacological Societies (1990-1997). The medal was created by EPHAR in 2014 to honour distinguished pharmacologists who have achieved merits for the discipline of Pharmacology in Europe.

The 2019 EACPT Congress will be held in Stockholm and the 2021 EACPT Congress in Athens.

The EACPT was founded 25 years ago and now includes as members all national organisations for clinical pharmacology in Europe, as well as organisations from further afield internationally. The EACPT aims to provide educational and scientific support for the more than 4000 individual professionals interested in clinical pharmacology and therapeutics throughout the European region, with its congresses attended by a global audience. The EACPT also advises policy makers on how the specialty can contribute to human health and wealth.

Clinical Therapeutics, the Official Journal of EACPT.


Friday, 14 April 2017

Pharmacology and therapeutics education in the EU needs harmonisation and modernisation


The EACPT has supported a European study of clinical pharmacology and therapeutics education which has now just been published in the journal Clinical Pharmacology & Therapeutics.

Effective teaching in pharmacology and clinical pharmacology and therapeutics (CPT) is necessary to make medical students competent prescribers. However, the current structure, delivery and assessment of CPT education in the European Union (EU) is unknown. 

In this study, the authors evaluated the current structure, delivery and assessment of clinical pharmacology and therapeutics education in the European Union. The authors conclude from a cross-sectional survey among 185 medical schools in 27 countries that pharmacology and therapeutics education in the EU needs harmonisation and modernisation. 

The manuscript is now freely accessible as an abstract and as a full paper through the journal.



Charles Bridge, Prague
22 sessions with Keynote Lectures on current issues for research, education and clinical practice on safe and effective use of medicines  
- almost 500 oral and poster presentations from the European Region and around the world  
- opportunity to network with global experts and trainees in the fields of research, clinical practice, the biotechnology sector, regulation and health policy  
- update on the activities of the EACPT Working Groups for Research, Education, Regulation and Young Pharmacologists.



Anyone from anywhere in the world with a professional interest in clinical pharmacology and/or therapeutics can now join the EACPT as an Individual Associate member. 

There are reduced joining fees for Individual Associate members who are already members of a national or international organisation relevant to clinical pharmacology and therapeutics.

Friday, 7 April 2017

Register for updates on safety and effectiveness of medicines at EACPT Prague Congress - 24-27 June 2017


Rotterdam 7th April, 20017

The EACPT Executive Committee are meeting in Rotterdam to agree final details of the next EACPT Congress to be held in Prague from 24-27 June 2017.


Early registration deadline 17 April
Standard registration deadline 16 June
Highlights of the Congress will include

22 sessions with Keynote Lectures on current issues for research, education and clinical practice on safe and effective use of medicines  
- almost 500 oral and poster presentations from the European Region and around the world  
- opportunity to network with global experts and trainees in the fields of research, clinical practice, the biotechnology sector, regulation and health policy  
- update on the activities of the EACPT Working Groups for Research, Education, Regulation and Young Pharmacologists.
 
Charles Bridge - Prague

The programme will provide an international scientific and educational forum for discussion of clinical pharmacology and therapeutics, including personalised pharmacotherapy.
Themes will include the latest developments on effectiveness and safety of medicines, clinical pharmacology in clinical practice, pharmacokinetics/systems pharmacology, including in special populations, innovative techniques, eHealth, biomarkers, education, advanced practices in topics such as drug discovery, drug development, biological therapies, global health with a focus on access to safe medicines, new pharmacology and pharmacotherapy, safety in prescribing and updates on personalised medicines, as well as updates on specific therapeutic areas, including cardiovascular disease, infectious disease, nephrology, oncology, neurology and psychiatry.


Anyone from anywhere in the world with a professional interest in clinical pharmacology and/or therapeutics can now join the EACPT as an Individual Associate member. 
There are reduced joining fees for Individual Associate members who are already members of a national or international organisation relevant to clinical pharmacology and therapeutics.

Membership benefits include:
* Discounted registration fees for EACPT meetings
* Online access to the Official EACPT Journal - Clinical Therapeutics
* Access to the EACPT’s worldwide network of Individual Associate Members
* Active involvement in EACPT

The 2019 EACPT Congress will be held in Stockholm and the 2021 EACPT Congress in Athens.

The EACPT was founded 25 years ago and now includes as members all national organisations for clinical pharmacology in Europe, as well as organisations from further afield internationally. The EACPT aims to provide educational and scientific support for the more than 4000 individual professionals interested in clinical pharmacology and therapeutics throughout the European region, with its congresses attended by a global audience. The EACPT also advises policy makers on how the specialty can contribute to human health and wealth.

Clinical Therapeutics, the Official Journal of EACPT.

Tuesday, 14 March 2017

Personalised Medicines and the European Medicines Agency

London, 14th - 15th March
The European Medicines Agency is hosting workshops for its Working Parties of  Patients', Consumers' and Health Professionals' organisations.

The 14th March workshop aims to create awareness among these organisations of how the work of the European Medicines Agency (EMA) relates to personalised medicines

The 15th March workshop provides updates on other EMA and relevant external acfivities including feedback on topic groups on Social Media and on Risk Minimisation from medicines, European Antibiotic Awareness, Action plans on Biosimilars, feedback from key EMA committees and synergies with other organisations.

Key aims
- understanding how European and global landscapes are shaping policy developments
- illustrating how activities of the European medicines regulatory network contribute to personalised medicine with existing legislation and regulatory tools
- discussing how clinical practice and public participation can support personalised medicine in the context of European Union (EU) regulatory activities
- identifying areas requiring attention from EU regulators, patients, healthcare professionals and civil society at large
- reflection by the working parties on priority areas for future contributions in broader multi-stakeholder discussions. 

Speakers include:  
- Sandra Kweder from the US Food and Drugs Administration, discussing  the US precision medicine initiative. She highlighted the need to personalise medicines with cancer a key driver - only 80% of patients estimated to respond better when individual genomic and proteomic information is available.

- briefings from EMA's Scientific Committees e.g.  PRAC chair June Raine discussing pharmacogenomics in pharmacovigilance e.g. preventing serious skin reactions to abacavir in HIV patients and limiting toxicity of anti-cancer agents e.g. 5-fluoro-uracil and capecitabine

- updates from research organizations e.g. Denis Lacombe from EORTC  (European Organisation for Research and Treatment of Cancer) on changing clinical research pathways, very expensive drugs and data-driven healthcare from "-omics" to "economics".
 
- developing diagnostics and treatments for rare diseases e.g. from Julian Isla on improving management of Dravet Syndrome - a rare, catastrophic, lifelong form of epilepsy that begins in the first year of life with frequent and/or prolonged seizures. 

- Ulrich Jäger from the European Haematology Association https://www.ehaweb.org/ on health professional perspectives on precision medicine, including practical challenges to applying precision medicine within a typical 7-12 minute consultation.    

- Dominique Monnet from the ECDC [European Centre for Disease Prevention and Control] reported on progress in developing European Antibiotic Awareness days, held annually on 18th November. The ECDC is mandated to monitor current and potential future risks to human health from communicable disease. Individual EU member states are responsible for risk management of established communicable disease.






The EACPT was founded 24 years ago and now includes as members all national organisations for clinical pharmacology in Europe, as well as organisations from further afield internationally. The EACPT aims to provide educational and scientific support for the more than 4000 individual professionals interested in clinical pharmacology and therapeutics throughout the European region, with its congresses attended by a global audience. The EACPT also advises policy makers on how the specialty can contribute to human health and wealth.

Thursday, 16 February 2017

2017 EACPT Lifetime Achievement Award to go to Professor Pertti Neuvonen from Finland


The EACPT is  delighted to announce that the 2017 Lifetime Achievement Award of the European Association of Clinical Pharmacology and Therapeutics will go to Professor Pertti J. Neuvonen from Finland for his outstanding contribution to the national and international benefits of clinical pharmacology for medicine, health care and patient safety.
The Award, which includes the EACPT silver medal, will be presented to Professor Neuvonen during the 13th EACPT Congress in Prague. The Congress runs from 24th - 27th June 2017.

Professor Emeritus Pertti J. Neuvonen
Professor Emeritus Pertti J. Neuvonen, whose research focuses on drug safety and individual variability in drug response, particularly on drug interactions and their mechanisms, is one of the most cited clinical pharmacologists in the world, with over 20,000 citations. He has been listed by Thomson Reuters for years as an ISI Highly Cited Researcher in Pharmacology. He has authored over 500 original articles and reviews. Of the original papers, 92 have been published in the journal Clinical Pharmacology & Therapeutics. He has supervised around 50 Doctoral (PhD) thesis projects. 
Since 1970, Neuvonen´s research group has found more than 200 previously unrecognized, clinically important drug-drug interactions and several significant food-drug interactions. Furthermore, his group demonstrated, already in the 1980-90s, the efficacy of activated charcoal as gastric decontaminator, compared with induced emesis and gastric lavage. The drug interaction studies in humans were deepened by in vitro studies to explore mechanism, predictability and avoidance of the interactions. His group observed that inhibition and induction of CYP3A4/5-enzyme could cause over 10-fold changes in exposure to several drugs (midazolam, triazolam, buspirone, felodipine, simvastatin, lovastatin). 
Furthermore, his group discovered among generally used drugs many previously unrecognized inhibitors of drug metabolism (itraconazole: CYP3A4; gemfibrozil and clopidogrel: CYP2C8) and unexpected victim substrates (tizanidine: CYP1A2; cerivastatin, repaglinide, pioglitazone, rosiglitazone, loperamide, montelukast: CYP2C8). In addition to drug metabolizing enzymes, also membrane transporters (e.g., OATP1B1, P-glycoprotein, BCRP), and their pharmacogenetics and interactions were found to affect pharmacokinetics (e.g., statins) and drug response. Many of the original findings made by Neuvonen and his research groups have been adopted into textbooks, guidelines (e.g., FDA) and product information texts.
Pertti Neuvonen was born in Kirvu (Finland) on 25. August 1943. He is married and has five adult children. He studied medicine at the University of Helsinki between 1964 and 1970, and defended his doctoral thesis at this University in 1971. From 1971 to 1972, he was as a fellow of the Alexander von Humboldt-Foundation in Hannover Medical School (Germany). From 1972-1985, he was Senior Lecturer/Assistant Professor/Consultant of Clinical Pharmacology, and from 1986-1988 Acting Professor and Head Physician of Clinical Pharmacology at University of Helsinki and University Central Hospital, including the National Poison Information Centre. Between 1988 and 1991, he was Professor and Chairman of Pharmacology at University of Turku. From 1992 to 2011, he was Professor and Head of Clinical Pharmacology at University of Helsinki and University Central Hospital. After his retirement in 2011, he continues his studies at the Department of Clinical Pharmacology as a free researcher. In 2011, he received the BCPT Nordic Prize in Basic & Clinical Pharmacology & Toxicology, and the Medal of the FDA Office of Clinical Pharmacology.
The EACPT was founded 24 years ago and now includes as members all national organisations for clinical pharmacology in Europe, as well as organisations from further afield internationally. The EACPT aims to provide educational and scientific support for the more than 4000 individual professionals interested in clinical pharmacology and therapeutics throughout the European region, with its congresses attended by a global audience. The EACPT also advises policy makers on how the specialty can contribute to human health and wealth.

Tuesday, 17 January 2017

ADAPTSMART: Accelerated Development of Appropriate Patient Therapies -

London, EMA, 17th January 2017: ADAPT SMART is a  platform funded by the European Union's IMI (Innovative Medicines Initiative) for the coordination of Medicines Adaptive Pathways to Patients (MAPPs) activities, involving multi-stakeholder approaches from research through to treatment outcomes.

MAPPs seek to foster access to beneficial treatments for the right patient groups at the earliest appropriate time in the product life-span in a sustainable fashion.

The European Medicines Agency is today hosting at Canary Wharf in London an expert workshop on ADAPTSMART, with delegates from throughout the European Region, from the Japanese medicines agency and elsewhere.

Topics include:

- appropriate use of medicines

- timely access to innovative medicines and other interventions

- early access medicine schemes

- protected therapeutic schemes e.g. cancer access funds

 - compassionate use

- expanded access pathways

- shortened timelines for approvals

- international comparisons for consequences of inappropriate prescribing - non-compliance with treatment guidelines. Differences will be considered where reimbursement is linked to compliance with prescribing guidelines.

See more on the ADAPTSMART website about key work packages and other aspects.